DBD CFO Thomas Timko buys 672 shares at $74.36 ($50.0K) as stock sits -16.6% from 52-week high
Thomas S Timko, EVP and CFO of Diebold Nixdorf, purchased 672 shares of DBD at $74.36 on 2026-05-22 for a total of $49,969.92, bringing his post-transaction holdings to 75,480 shares. The purchase comes as DBD trades -16.6% from its 52-week high and has declined -11.8% over the past 30 days and -8.5% over the past 90 days. His two prior open-market purchases at DBD — on 2024-11-12 and 2024-08-09 — each produced positive returns at the 90-day mark (+8.2% and +11.2% respectively), giving him a 2 of 2 well-timed record at this ticker. His cross-ticker track record also reflects 2 prior buys with an avg 90d return of +9.7% and a 90d win rate of 100.00%.
DBD CFO Timko buys 360 shares at $40.75 as part of cluster buy; company unprofitable, stock down 11.8% in 30d.
CFO Thomas S Timko purchased 360 shares of Diebold Nixdorf at $40.75 on 2024-11-12, increasing his holdings to 48.6K shares. This buy occurs within a 14-day cluster pattern where 2 other insiders also purchased, and it follows a prior DBD buy on 2024-08-09 that returned +5.8% over 30 days and +11.2% over 90 days. However, context is material: the company reported -$22.4M net income in the latest quarter and -11.4% annual revenue decline, with the stock trading 18.8% below its 52-week high and down 11.8% over the past 30 days. The coordinated insider purchases suggest internal confidence during a period of operational challenge and recent weakness.
DBD CFO Thomas Timko buys 1.4K shares at $38.71; stock down 4.0% in 30d, 7.7% in 90d.
Thomas Timko, EVP and CFO of Diebold Nixdorf, purchased 1,400 shares at $38.71 on 2024-08-09 for $54,189.52, increasing his holdings to 48,219 shares. The transaction occurred as DBD stock was trading below its 52-week high of $44.60 and has declined 4.0% in the 30 days and 7.7% in the 90 days since the purchase. The company faces headwinds: annual revenue growth was -11.4% and the company was unprofitable over its most recent full fiscal year, with the latest quarterly net income of $14.9M offset by broader negative annual performance. While Timko's cross-ticker track record shows a 100.00% well-timed rate on his 1 prior sell, that limited history and cross-ticker scope provides minimal predictive signal for this single DBD purchase. The modest share increase (+3.0% of prior holdings) and modest price decline post-purchase warrant monitoring of whether management is actively stabilizing shareholder value or simply maintaining baseline confidence amid operational decline.
